CONNECT II, a global trial that will test the first-ever chronic total
occlusion crossing catheter to use optical coherence tomography, has enrolled
its first US patient, according to a press release.
The announcement came just 2 weeks after the first European patient was
enrolled in the trial in Mirano, Italy.
The prospective, nonrandomized CONNECT II trial will test the catheter
(Ocelot, Avinger) in 100 patients with peripheral arterial disease and
femoropopliteal CTO lesions at 17 sites, including three in the European Union,
where the device received CE Mark approval in 2011. Trial co-principal
investigators include Arne Schwindt, MD, of St. Franziskus Hospital in
Muenster, Germany, and Matthew Selmon, MD, from the Austin Heart
Hospital in Austin, Texas.